Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Aplenc

Showing results (131-140 of 254) with videos related to

Pageof 26
Sort By:
Journal of the Pediatric Infectious Diseases Society|December 2, 2015
Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic LeukemiaBrian T Fisher, Julia Shaklee Sammons, Yimei Li, et al.
Neuro-Oncology|January 12, 2022
Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1Chelsea Kotch, Robert Avery, Kelly D Getz, et al.
Journal of Clinical Pharmacology|April 19, 2017
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age RangeMichael J Hanley, Diane R Mould, Timothy J Taylor, et al.
Pediatric Blood & Cancer|April 15, 2024
Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective studyJuliette Renaud, Bianca F Goemans, Franco Locatelli, et al.
BMC Medical Genetics|June 2, 2011
Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major traumaMelanie Rushefski, Richard Aplenc, Nuala Meyer, et al.
American Journal of Hematology|November 19, 2016
The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemiaLena E Winestone, Kelly D Getz, Tamara P Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology GroupRichard Aplenc, Todd A Alonzo, Robert B Gerbing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2021
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i>-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531Jessica A Pollard, Erin Guest, Todd A Alonzo, et al.
Journal of the National Cancer Institute|November 23, 2020
Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk NeuroblastomaKira Bona, Yimei Li, Lena E Winestone, et al.
Pediatric Blood & Cancer|September 2, 2021
Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology GroupKelly D Getz, Todd A Alonzo, Lillian Sung, et al.
Pageof 26

Showing results (131-140 of 254) with videos related to

Sort By:
Pageof 26
Journal of the Pediatric Infectious Diseases Society|December 2, 2015
Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic LeukemiaBrian T Fisher, Julia Shaklee Sammons, Yimei Li, et al.
Neuro-Oncology|January 12, 2022
Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1Chelsea Kotch, Robert Avery, Kelly D Getz, et al.
Journal of Clinical Pharmacology|April 19, 2017
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age RangeMichael J Hanley, Diane R Mould, Timothy J Taylor, et al.
Pediatric Blood & Cancer|April 15, 2024
Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective studyJuliette Renaud, Bianca F Goemans, Franco Locatelli, et al.
BMC Medical Genetics|June 2, 2011
Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major traumaMelanie Rushefski, Richard Aplenc, Nuala Meyer, et al.
American Journal of Hematology|November 19, 2016
The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemiaLena E Winestone, Kelly D Getz, Tamara P Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology GroupRichard Aplenc, Todd A Alonzo, Robert B Gerbing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2021
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i>-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531Jessica A Pollard, Erin Guest, Todd A Alonzo, et al.
Journal of the National Cancer Institute|November 23, 2020
Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk NeuroblastomaKira Bona, Yimei Li, Lena E Winestone, et al.
Pediatric Blood & Cancer|September 2, 2021
Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology GroupKelly D Getz, Todd A Alonzo, Lillian Sung, et al.
Pageof 26